JAK/STAT signaling has served as the primary target for MPN specific drug development and has led to the approval of two small-molecule JAK2 inhibitors, ruxolitinib and fedratinib [2, 9, 10]. This evidence concerns the gene SOAT1 and myeloproliferative neoplasm.